Jump to content

AB123

Members
  • Posts

    106
  • Joined

  • Last visited

  • Days Won

    3
  • Country

    Thailand

AB123 last won the day on March 14 2021

AB123 had the most liked content!

Profile Information

  • Gender
    Male
  • Occupation
    Blood Bank Manager

Recent Profile Visitors

2,467 profile views

AB123's Achievements

  1. They requested by e-mail and haven't sent any official sharing links so I guess there expecting them back by e-mail which from what I've found from the CAP website is not one of the acceptable ways of sharing documents in advance., and yes, the list is 3 sides of A4 paper long so its a pretty large list. I did find the below on the CAP website, and it seems there is an option to "Opt" for advanced document review, however we have not, so I think we will be declining this. Thanks
  2. We have an upcoming CAP inspection for all Lab sections and today we have received a big list of documents, Policies and Procedures etc, that one of the inspectors wants us to send them in advance. This is the first time we have experienced this with CAP especially as its an onsite, not remote inspection. Thoughts on this?
  3. We have an nonconformance for temperature alarm activation testing, as per the assessor they wanted to see the alarm activation at exactly the set alarm temperature. I feel this is unrealistic to get it exactly on the set activation temperature. Is there any references or guidance on this I can follow for what is required? I've looked in the AABB Technical manual but don't seem to be able to find anything specific, what I'm looking for is some guidance on how close to the stated alarm activation temperature, the alarm must activate. Thanks
  4. In our part of the world we are unable to purchase any commercially available Kleihauer reagents/kits, we have started making our own from the base chemicals following the method described in the AABB test method guide. I'm assuming this would constitute a LDT under CAP? in this case for validation and QC purposes what would we have to do in addition to the usual test method validation and QC's with every batch? if anything. Just to clarify, we are making up the Citrate phosphate buffer and the Eosin solution, the Hematoxylin is a commercially supplied. TIA
  5. Chido and Rodgers can be neutralized with Chido/Rodgers positive plasma, what are the antibody characteristics that suggest such an antibody that make you decide to do the antibody neutralization? My understanding is they will be pan-reactive with most if not all identification panel cells and non reactive in enzyme, are there any other characteristics that should lead to the decision to try neutralization or should it be performed on any pan-reactive, non enzyme reactive AB? Thanks
  6. 5.3 Timing of samples The maternal sample for FMH estimation should be taken when sufficient time has elapsed to allow fetal cells to be distributed within the maternal circulation following delivery, manual removal of placenta or sensitising event. A period of 30-45 minutes is considered adequate (BCSH 2006a). BCSH FMH Guidelines 2009
  7. We have a blood transfusion administration module in our HIS, on receipt on the ward they have to scan the unit against the patients electronic record, if it doesn't match the patient it was issued for, it will not allow them to proceed with the administration. I am working to further enhance this by incorporating patient wrist band scan at the same time at the patients bed side.
  8. I want to introduce the Rosette test for FMH screening, unfortunately no commercial kits are available in the UAE where I am based. Right now I cannot even find a Keilhauer staining kit. Does any one use an in house method for this test? if so what Anti-D reagent do you use? AABB have a method which just states high protein Anti-D reagent, can anyone offer any further advice on selecting a suitable Anti-D antisera for use with this method? Thanks
  9. I am looking for a method for performing Hemolysin Titres on blood components, does anyone have one they would be willing to share? Thanks
  10. The thirty year rule came from the European blood directive 2002/98/EC, the NHS is only UK based, this was a European wide requirement. https://www.health-ni.gov.uk/articles/blood-safety-and-quality-regulations-2005-amended#:~:text=The Regulations,-The retention periods&text=Blood establishments and hospital blood,(regulations 8 and 9). Also there is no such 30 year limit on suing the NHS, its 3 years from the date of discovery, so if you didn't find out until 50 years later then it would be 53 years. Applicable Time Limits To Sue The NHS Claimant immediately aware that negligence had caused avoidable harm 3 years from the date of the negligent act Claimant made aware later that negligence had caused avoidable harm 3 years from the date of the discovery Those without capacity No limit (There are some limits to those claiming on the injured party’s behalf – please see later sections or call our team for specific guidance)
  11. Wasn't 30 years due to vCJD risk? as the incubation period can be 20 years+ hence records need to be kept this long at least for tracing potential donor and other recipients from same donor? With regards to record keeping, in my experience in the UK while we kept the administration record of the anti-D the same as we did for all blood components/products, 30 years. Once we were satisfied that the anti-D was not of immune origin we would remove the record from the antibody file otherwise we would not be able to use electronic issue for future crossmatches. Our LIS was such though that it would stay in the audit log of the patients file indefinitely that it was added then removed.
  12. And also my reason for asking which antigens are most likely, so I know which ones to try first rather than ordering them all.
  13. I'm looking into sourcing these from a company in Germany called inno-train who provide molecular blood typing products also, I believe from the name in the IFU's provided these are the same (imusyn GmbH & Co. KG.) that you mention above. My next question was going to be if anyone has any feedback on these techniques? imusyn rBGA Kits_v19_EN_RUO.pdf
  14. Column agglutination with glass beads instead of Gel from Ortho.
  15. We run auto control with all our panels and in these cases they are negative, were a women's speciality hospital in the middle east. I'm literally getting 3 or 4 of these a week and we have no reference service so mostly they are going unidentified. I'm trying to develop our identification protocols and source additional reagents to help ID these cases but struggling to find HFA negative cells out here. Just to add in most cases these are pregnant women.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.